top of page
Executive Spotlights

Aiolos Bio Launches with $245M Series A

San Francisco & London, October 24, 2023 (Business Wire) -- Aiolos Bio, Inc. has launched as a clinical-stage biopharmaceutical company that aims to address the unmet respiratory and inflammatory treatment needs of patients. The company has raised $245 million in a Series A investment round, co-led by Atlas Venture, Bain Capital Life Sciences, Forbion, and Sofinnova Investments, with additional investment from RA Capital Management. Aiolos Bio’s lead drug candidate, AIO-001, will be advanced into a Phase 2 clinical trial for moderate-to-severe asthma patients, and the company is actively exploring additional development opportunities.

Read full article here.

Recent Posts

See All

Radiant Vision Systems Appoints new CEO

Redmond, WA, July 1, 2024 (Radiant) -- Radiant Vision Systems has appointed Stone Jiang as their new CEO, succeeding Doug Kreysar who is retiring. Jiang, previously the Executive Vice President and

Orion and Merck Secure $1.63B Agreement

Rahway, NJ, July 1, 2024 (Business Wire) -- Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, and Orion Corporation ("Orion") have agreed to convert their co-development and co-commercial


Life Science Headlines
bottom of page